Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$15.78
+0.1%
$16.49
$3.25
$21.48
$423.03M1.18263,508 shs149,183 shs
IO Biotech, Inc. stock logo
IOBT
IO Biotech
$1.44
$1.29
$0.66
$1.73
$94.87M0.36283,785 shs87,727 shs
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$10.23
0.0%
$9.17
$4.80
$18.13
$390.97M1.49690,626 shs224,146 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.35
-3.1%
$3.95
$2.41
$10.37
$414.68M2.341.20 million shs916,342 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-0.19%+8.91%-0.50%+31.75%+359.77%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
-0.69%-3.36%-7.10%+67.87%+22.03%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
+1.09%+0.69%+1.89%+97.49%-32.30%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+5.34%+13.35%+19.48%+106.74%-17.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.6129 of 5 stars
3.53.00.00.01.81.70.6
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3.2619 of 5 stars
3.73.00.00.02.82.50.6
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.2896 of 5 stars
4.12.00.00.01.93.30.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.2701 of 5 stars
4.62.00.00.01.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3.00
Buy$29.6789.38% Upside
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3.33
Buy$9.33552.68% Upside
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.14
Hold$15.8655.39% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10182.35% Upside

Current Analyst Ratings Breakdown

Latest IOBT, SLDB, ITOS, and ETON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/29/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $35.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$10.00 ➝ $12.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $26.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$39.01M10.77N/AN/A$0.94 per share16.66
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/A$0.71 per shareN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M11.16N/AN/A$16.16 per share0.63
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M51.24N/AN/A$3.43 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$3.82M-$0.18N/A31.33N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)
IO Biotech, Inc. stock logo
IOBT
IO Biotech
-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)

Latest IOBT, SLDB, ITOS, and ETON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/13/2025Q1 2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million
4/28/2025Q1 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
1.23
1.97
1.43
IO Biotech, Inc. stock logo
IOBT
IO Biotech
N/A
2.32
2.32
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.13
14.13
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89

Institutional Ownership

CompanyInstitutional Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
54.76%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
16.03%
IO Biotech, Inc. stock logo
IOBT
IO Biotech
4.80%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2026.82 million22.52 millionOptionable
IO Biotech, Inc. stock logo
IOBT
IO Biotech
3065.88 million62.72 millionNot Optionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million33.49 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.51 million76.04 millionOptionable

Recent News About These Companies

SLDB Solid Biosciences Inc. - Seeking Alpha
Solid Biosciences Inc. (SLDB) - Yahoo Finance
SLDB - Solid Biosciences Inc Valuation - Morningstar
Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance
Brokers Offer Predictions for SLDB FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eton Pharmaceuticals stock logo

Eton Pharmaceuticals NASDAQ:ETON

$15.78 +0.01 (+0.09%)
As of 02:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

IO Biotech stock logo

IO Biotech NASDAQ:IOBT

$1.44 0.00 (0.00%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$10.22 -0.01 (-0.05%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.35 -0.17 (-3.08%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.